KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBITDA (2016 - 2025)

Sarepta Therapeutics has reported EBITDA over the past 15 years, most recently at -$411.6 million for Q4 2025.

  • For Q4 2025, EBITDA fell 354.56% year-over-year to -$411.6 million; the TTM value through Dec 2025 reached -$694.8 million, down 390.49%, while the annual FY2025 figure was -$699.8 million, 420.88% down from the prior year.
  • EBITDA for Q4 2025 was -$411.6 million at Sarepta Therapeutics, down from -$179.7 million in the prior quarter.
  • Over five years, EBITDA peaked at $196.8 million in Q2 2025 and troughed at -$515.5 million in Q1 2023.
  • A 5-year average of -$105.6 million and a median of -$93.4 million in 2021 define the central range for EBITDA.
  • On a YoY basis, EBITDA climbed as much as 3115.28% in 2025 and fell as far as 970.43% in 2025.
  • Year by year, EBITDA stood at -$122.0 million in 2021, then increased by 11.71% to -$107.7 million in 2022, then soared by 143.83% to $47.2 million in 2023, then skyrocketed by 242.46% to $161.7 million in 2024, then plummeted by 354.56% to -$411.6 million in 2025.
  • Business Quant data shows EBITDA for SRPT at -$411.6 million in Q4 2025, -$179.7 million in Q3 2025, and $196.8 million in Q2 2025.